Project Grant R01EY037934
- Federal Grant Award Summary Duke University received a $675,193 Project Grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), awarded September 1, 2025, with completion expected June 30, 2028. The grant supports research into gene therapy targeting complement factor H (CFH) and lipoprotein dynamics in age-related macular degeneration (AMD). The research leverages novel animal models developed by the investigative team that integrate advanced age, complement...
- Federal Grant Award Summary The National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), awarded University of California, Davis a $719,012 Project Grant effective August 1, 2025, through July 31, 2030, to optimize suprachoroidal adeno-associated virus (AAV) delivery systems for retinal gene therapies in nonhuman primates. The research addresses significant limitations of conventional AAV administration routes by evaluating microcatheterization techniques and...
- Federal Project Grant Award Summary The National Eye Institute (NEI) awarded $173,016 to the Whitehead Institute for Biomedical Research under the Vision Research program (CFDA 93.867) for a project grant effective August 1, 2025, through July 31, 2027. This award supports systematic identification and mechanistic characterization of novel oxidative protective genes to prevent retinal pigment epithelium (RPE) degeneration in age-related macular degeneration (AMD). The research involves...
- Summary of Federal Project Grant Award The National Eye Institute (NEI) awarded a $422,125 Project Grant to the University of Miami's Office of Research Administration—School of Medicine on August 1, 2025, under the Vision Research program (CFDA 93.867) for a two-year project period concluding July 31, 2027. This award funds research investigating cholesterol homeostasis as a therapeutic target for demyelinating eye diseases, which are pathologies affecting the optic nerve that can cause...
- Federal Project Grant Award Summary The National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) awarded $902,000 to the University of California, San Francisco for a two-year project (September 1, 2025 – August 31, 2027) to conduct multimodal characterization of a novel inherited mouse model of glaucoma. The primary deliverables include comprehensive phenotypic characterization of GLIS1 knockout mice across two genetic backgrounds, evaluating structural and functional...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded The Schepens Eye Research Institute, Inc. a Project Grant of $423,866 under the Vision Research program (CFDA 93.867) to develop mini-USH2A gene therapy for treating Usher Syndrome Type 2A (USH2A), the most common inherited condition causing combined hearing and vision loss. The research project, which commenced May 1, 2026 and concludes April 30, 2028, focuses on creating a functional minigene construct that addresses the...
- Federal Grant Award Summary The National Eye Institute awarded a $498,000 Project Grant to Indiana University (Trustees of Indiana University) on September 15, 2025, under the Vision Research program (CFDA 93.867). This award supports fundamental research investigating the mechanisms of retinal plasticity and functional recovery following gene therapy for inherited retinal degenerations, specifically utilizing a mouse model of achromatopsia. The research deliverables include empirical findings...
- Federal Project Grant Award Summary Massachusetts Eye and Ear Infirmary received a $663,406 Project Grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), effective April 1, 2026 through March 31, 2031. The award funds research to develop novel adeno-associated virus (AAV)-based therapeutics targeting retinoic acid signaling pathways to preserve cone photoreceptor function in retinitis pigmentosa (RP), an inherited retinal disease affecting approximately 1...
- Federal Project Grant Award Summary The National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) awarded $733,137 to the University of California, Los Angeles on September 15, 2025, to support research exploring how genetic variation influences disease progression and therapeutic response in age-related macular degeneration (AMD). The project, with completion targeted for March 31, 2030, will deliver scientific research products including refined classification of AMD...
- Federal Project Grant Award Summary The National Eye Institute (NEI) awarded The Ohio State University $413,478 on September 22, 2025, under the Vision Research program (CFDA 93.867) to develop and test a novel pre-retinal gene therapy approach for inherited retinal disease (IRD). The primary deliverable is research investigating an insulin-accelerated surgical technique for adeno-associated virus (AAV) vector administration that addresses critical limitations of existing subretinal gene therapy...
Summary of Federal Project Grant Award The University of North Carolina at Chapel Hill received a $603,053 Project Grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), awarded April 15, 2026, with completion targeted for March 31, 2030. This award supports preclinical development of a gene augmentation therapy for IMPG2-associated retinal degeneration, a genetic condition causing juvenile-onset rod-cone dystrophy and adult-onset vitelliform macular dystrophy. The research leverages complementary in vitro and in vivo model systems—including patient-derived human retinal organoids derived from induced pluripotent stem cells and IMPG2-knockout mouse models—to optimize adeno-associated virus (AAV) vector designs for delivering functional IMPG2 gene sequences to photoreceptors and assess therapeutic safety and efficacy prior to clinical translation. The primary deliverables include preclinical trial endpoint definition using IMPG2-knockout mice, viral vector design optimization, and functional assessments of gene augmentation capacity to prevent retinal pathology and photoreceptor degeneration. These research products will establish the scientific and safety foundation necessary to advance toward human clinical trials for this currently untreated form of inherited retinal dystrophy. The award supports fundamental translational science within NEI's mission to drive innovative research aimed at preventing and treating vision diseases.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $603.1k | 4/17/26 |